Literature DB >> 16942122

Cost-of-illness studies : a review of current methods.

Ebere Akobundu1, Jing Ju, Lisa Blatt, C Daniel Mullins.   

Abstract

The number of cost-of-illness (COI) studies has expanded considerably over time. One outcome of this growth is that the reported COI estimates are inconsistent across studies, thereby raising concerns over the validity of the estimates and methods. Several factors have been identified in the literature as reasons for the observed variation in COI estimates. To date, the variation in the methods used to calculate costs has not been examined in great detail even though the variations in methods are a major driver of variation in COI estimates. The objective of this review was to document the variation in the methodologies employed in COI studies and to highlight the benefits and limitations of these methods. The review of COI studies was implemented following a four-step procedure: (i) a structured literature search of MEDLINE, JSTOR and EconLit; (ii) a review of abstracts using pre-defined inclusion and exclusion criteria; (iii) a full-text review using pre-defined inclusion and exclusion criteria; and (iv) classification of articles according to the methods used to calculate costs. This review identified four COI estimation methods (Sum_All Medical, Sum_Diagnosis Specific, Matched Control and Regression) that were used in categorising articles. Also, six components of direct medical costs and five components of indirect/non-medical costs were identified and used in categorising articles.365 full-length articles were reflected in the current review following the structured literature search. The top five cost components were emergency room/inpatient hospital costs, outpatient physician costs, drug costs, productivity losses and laboratory costs. The dominant method, Sum_Diagnosis Specific, was a total costing approach that restricted the summation of medical expenditures to those related to a diagnosis of the disease of interest. There was considerable variation in the methods used within disease subcategories. In several disease subcategories (e.g. asthma, dementia, diabetes mellitus), all four estimation methods were represented, and in other cases (e.g. HIV/AIDS, obesity, stroke, urinary incontinence, schizophrenia), three of the four estimation methods were represented. There was also evidence to suggest that the strengths and weaknesses of each method were considered when applying a method to a specific illness. Comparisons and assessments of COI estimates should consider the method used to estimate costs both as an important source of variation in the reported COI estimates and as a marker of the reliability of the COI estimate.

Entities:  

Mesh:

Year:  2006        PMID: 16942122     DOI: 10.2165/00019053-200624090-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  380 in total

1.  Household cost of seeking malaria care. A retrospective study of two districts in Ghana.

Authors:  W K Asenso-Okyere; J A Dzator
Journal:  Soc Sci Med       Date:  1997-09       Impact factor: 4.634

2.  Cost of stroke in The Netherlands from a societal perspective.

Authors:  S M Evers; G L Engel; A J Ament
Journal:  Stroke       Date:  1997-07       Impact factor: 7.914

3.  Cost of illness due to dementia in Sweden.

Authors:  A Wimo; G Karlsson; P O Sandman; L Corder; B Winblad
Journal:  Int J Geriatr Psychiatry       Date:  1997-08       Impact factor: 3.485

4.  The economic costs of caring for people with HIV infection and AIDS in England and Wales.

Authors:  S Petrou; M Dooley; L Whitaker; E Beck; E Kupek; J Wadsworth; D Miller; A Renton
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

5.  Medical care expenditures for diabetes, its chronic complications, and its comorbidities.

Authors:  T A Hodgson; A J Cohen
Journal:  Prev Med       Date:  1999-09       Impact factor: 4.018

6.  The cost of HIV/AIDS to businesses in southern Africa.

Authors:  Sydney Rosen; Jeffrey R Vincent; William MacLeod; Matthew Fox; Donald M Thea; Jonathon L Simon
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

7.  Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates.

Authors:  Edward Yelin; Miriam G Cisternas; David J Pasta; Laura Trupin; Louise Murphy; Charles G Helmick
Journal:  Arthritis Rheum       Date:  2004-07

8.  The relationship of body mass index, medical costs, and job absenteeism.

Authors:  Timothy Bungum; Monica Satterwhite; Allen W Jackson; James R Morrow
Journal:  Am J Health Behav       Date:  2003 Jul-Aug

9.  Relation between severity of Alzheimer's disease and costs of caring.

Authors:  M J Hux; B J O'Brien; M Iskedjian; R Goeree; M Gagnon; S Gauthier
Journal:  CMAJ       Date:  1998-09-08       Impact factor: 8.262

10.  Direct treatment costs for patients with lung cancer from first recurrence to death in france.

Authors:  Anne-Chantal Braud; Christine Lévy-Piedbois; Pascal Piedbois; Youri Piedbois; Alain Livartovski; Béatrice Le Vu; Jean Trédaniel; François Reboul; Yvelise Brewer; Said Talbi; François Blanchon; Britta Paschen; Isabelle Durand-Zaleski
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more
  77 in total

1.  Health impact metrics for air pollution management strategies.

Authors:  Sheena E Martenies; Donele Wilkins; Stuart A Batterman
Journal:  Environ Int       Date:  2015-09-14       Impact factor: 9.621

Review 2.  Cost-of-Illness Studies: An Updated Review of Current Methods.

Authors:  Eberechukwu Onukwugha; Jacquelyn McRae; Alex Kravetz; Stefan Varga; Rahul Khairnar; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

3.  The hidden economic burden of air pollution-related morbidity: evidence from the Aphekom project.

Authors:  Olivier Chanel; Laura Perez; Nino Künzli; Sylvia Medina
Journal:  Eur J Health Econ       Date:  2015-12-09

4.  Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Authors:  Ashit Syngle; Sudeep Kaur; Inderjeet Verma; Tanya Syngle; Vijaita Syngle
Journal:  Clin Rheumatol       Date:  2017-06-21       Impact factor: 2.980

5.  The impact of BMI on direct costs in children and adolescents: empirical findings for the German Healthcare System based on the KiGGS-study.

Authors:  Christina M Wenig
Journal:  Eur J Health Econ       Date:  2010-09-29

6.  Use of econometric models to estimate expenditure shares.

Authors:  Justin G Trogdon; Eric A Finkelstein; Thomas J Hoerger
Journal:  Health Serv Res       Date:  2008-01-31       Impact factor: 3.402

7.  Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.

Authors:  J Blouin; A Dragomir; M Fredette; L-G Ste-Marie; J C Fernandes; S Perreault
Journal:  Osteoporos Int       Date:  2008-12-24       Impact factor: 4.507

8.  The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach.

Authors:  Grégoire de Lagasnerie; Anne-Sophie Aguadé; Pierre Denis; Anne Fagot-Campagna; Christelle Gastaldi-Menager
Journal:  Eur J Health Econ       Date:  2017-02-11

9.  The economic burden of exposure to secondhand smoke for child and adult never smokers residing in U.S. public housing.

Authors:  Jacquelyn Mason; William Wheeler; Mary Jean Brown
Journal:  Public Health Rep       Date:  2015 May-Jun       Impact factor: 2.792

10.  The current economic burden of illness of osteoporosis in Canada.

Authors:  R B Hopkins; N Burke; C Von Keyserlingk; W D Leslie; S N Morin; J D Adachi; A Papaioannou; L Bessette; J P Brown; L Pericleous; J Tarride
Journal:  Osteoporos Int       Date:  2016-05-11       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.